Lucia Giovannetti

Dr. Lucia Giovannetti

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
DBDaiana Bezzini
Daiana Bezzini
LKLucia Kundisova
Lucia Kundisova
FGFrancesco Gori
Francesco Gori
AMAndrea Martini
Andrea Martini
LGLucia Giovannetti
Lucia Giovannetti
MBMario Alberto Battaglia
Mario Alberto Battaglia

7 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Giovanni Luca CeresoliGiovanni Luca Ceresoli
Giovanni Luca Ceresoli
SSSimona Stella
Simona Stella
BDBarbara Dallari Barbara Dallari
Barbara Dallari Barbara Dallari
RPRiccardo Perduri
Riccardo Perduri
CSCINZIA Storchi
CINZIA Storchi
Carolina MensiCarolina Mensi
Carolina Mensi
Background: Mesothelioma of the tunica vaginalis testis (MTVT) is an exceedingly rare tumor. We performed a registry-based study on MTVT patient management and survival in Italy. Methods: Cases were extracted from the dataset of the Italian National Mesothelioma Registry. A descriptive analysis of patient characteristics, including asbestos exposure, clinical presentation, diagnostic work-up and therapeutic management, was performed. Overall survival was evaluated. We calculated hazard ratios (HR) and 95% confidence intervals (CI) for selected variables by fitting univariate and multivariable Cox models. Results: Overall, 104 patients with MTVT were included. Median age was 72 years (range 17–92). Epithelioid histotype was the most frequent. Previous asbestos exposure was identified in two thirds of cases. Data on diagnostic and therapeutic management were available for 74 patients (71%). The most frequent presentations were scrotal swelling/mass, hydrocele and inguinal pain. All patients underwent surgery, mostly with orchi-funicolectomy. Adjuvant therapy was administered to 15 patients (20%). Overall median survival was 26.2 months (95% CI 22.1–52.1); 3-, 5- and 10-year survival was 49%, 30% and 18%. Older age at diagnosis and presence of distant metastasis (HR 1.91, CI: 0.85–4.26) were negative prognostic factors. Adjuvant therapy was associated with higher mortality (HR 2.54, CI: 1.25–5.15), indicating a more advanced stage at diagnosis. Conclusions: Surgery remains the mainstay of treatment for MTVT; adjuvant therapy in our study did not improve outcome. Data from cancer registries are essential for rare cancers, but they should be integrated routinely with additional diagnostic and therapeutic information.

1 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SSSimona Stella
Simona Stella
Dario ConsonniDario Consonni
Dario Consonni
Giovanni Luca CeresoliGiovanni Luca Ceresoli
Giovanni Luca Ceresoli
BDBarbara Dallari Barbara Dallari
Barbara Dallari Barbara Dallari
RPRiccardo Perduri
Riccardo Perduri
Carolina MensiCarolina Mensi
Carolina Mensi
Background: Pericardial mesothelioma (PM) is an extremely rare cancer with a poor prognosis and no consensus on diagnostic and therapeutic management. We conducted a registry-based study on PM cases in Italy diagnosed between 1993 and 2021. Methods: Based on data from the Italian National Mesothelioma Registry (ReNaM), we performed a descriptive analysis of PM cases including clinical presentation, diagnostic work-up, asbestos exposure, and therapeutic management. Overall survival was calculated. Hazard ratios (HRs) and 95% confidence intervals (CI) for selected variables were estimated with univariate and multivariate Cox models. Results: We identified 72 cases (46 men and 26 women). Median age was 66 years (range 22–89). The most frequent histological subtypes were epithelioid and unspecified mesothelioma. Almost two-thirds of cases had been exposed to asbestos. The most common clinical presentation was pericardial effusion. Overall median survival was 2.8 months (95% CI 1.2–6.6) and older age at diagnosis was a negative prognostic factor. Clinical and treatment data were available for 47 patients (65%). Approximately one out of two patients underwent surgery (palliative, in one-third of cases). Adjuvant therapy was administered to seven patients (15%). In cases with treatment information, sarcomatoid subtype (HR 2.74, 95% CI: 1.06–7.06) was a negative prognostic factor; adjuvant therapy was associated with better survival (HR 0.38, 95% CI 0.14–1.02), but confounding by indication cannot be excluded. Conclusions: We confirmed the very poor prognosis of PM. An international network collecting PM cases with treatment information is needed to improve patient quality of life and survival.

27 March 2026 in Journal of Epidemiology and Community Health
Verified
Journal Article
Closed access
Alessandro MarinaccioAlessandro Marinaccio
Alessandro Marinaccio
CGClaudio Gariazzo
Claudio Gariazzo
Carolina MensiCarolina Mensi
Carolina Mensi
DCDario Consonni
Dario Consonni
CGCarmela Gioscia
Carmela Gioscia
ABAlessandra Binazzi
Alessandra Binazzi
Background: In Italy, the 1992 asbestos ban prohibited all forms of asbestos production, use and importation. The epidemiological surveillance of mesothelioma mortality and incidence enabled the assessment of the ban’s impact and subsequent phases in asbestos exposure patterns. Methods: To estimate the effects of the ban, a quasi-Poisson generalised linear model was used to fit past asbestos consumption with mesothelioma mortality by gender, using distributed lag non-linear models and different asbestos consumption scenarios with and without ban. Mesothelioma cases in the period 1993–2021 were categorised based on type of asbestos exposure and economic sector of activities involved, to examine their temporal trend and geographical distributions. Results: The avoided number of mesothelioma deaths was estimated to be between 8341 and 21 981 in the period 1992–2020, depending on asbestos use scenario. As for incidence, 37 003 cases were collected between 1993 and 2021. The causal role of direct asbestos use (mining and milling ore and processing asbestos in asbestos-cement and asbestos-textile industry) changed from 11.3% for cases between 1993 and 1996 to 3.2% in the most recent cases (2017–2021). Inversely, cases due to unexpected or atypical exposure to asbestos and in construction increased from 11.3% in 1993–1996 to 17.0% in 2017–2021, and from 12.9% to 21.4%, respectively. Conclusions: The asbestos ban in Italy has produced substantial health benefits, with many deaths avoided. Countries that still use asbestos should consider evidence of the effects of asbestos bans, as well as the relationship between trends in mesothelioma cases and changing patterns of asbestos exposure.